Form 8-K - Current report:
SEC Accession No. 0001437749-24-035331
Filing Date
2024-11-14
Accepted
2024-11-14 16:27:35
Documents
16
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K inbp20241112_8k.htm   iXBRL 8-K 43424
2 EXHIBIT 99.1 PRESS RELEASE DATED 11 13 2024 ex_746768.htm EX-99.1 44213
7 ibp_logo.jpg GRAPHIC 12671
  Complete submission text file 0001437749-24-035331.txt   231190

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inbp-20241113.xsd EX-101.SCH 3411
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inbp-20241113_def.xml EX-101.DEF 10355
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE inbp-20241113_lab.xml EX-101.LAB 13838
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inbp-20241113_pre.xml EX-101.PRE 10350
18 EXTRACTED XBRL INSTANCE DOCUMENT inbp20241112_8k_htm.xml XML 2550
Mailing Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205
Business Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205 9739260816
INTEGRATED BIOPHARMA INC (Filer) CIK: 0001016504 (see all company filings)

EIN.: 222407475 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-31668 | Film No.: 241463004
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)